Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1

Interventions

Nivolumab 3sargramostim 2pembrolizumab 2atezolizumab 2Platinum 2Cyclophosphamide 2tazemetostat 1regorafenib 1enzalutamide 1entinostat 1durvalumab 1cemiplimab 1cabozantinib 1avelumab 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Pemetrexed 1Paclitaxel 1Microarray Analysis 1Levoleucovorin 1Leucovorin 1Ipilimumab 1Interleukin-2 1Interferon-gamma 1Interferon-alpha 1In Situ Hybridization, Fluorescence 1Immunoenzyme Techniques 1Immune Checkpoint Inhibitors 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gene Expression Profiling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × BAY 1895344 × Genitourinary × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡